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Introduction. Vitamin D deficiency is a common problem in end-
stage renal disease patients under hemodialysis. Both active and 
nutritional vitamin D supplementation have been recommended 
for its treatment. In this study we aimed to evaluate the effects 
of treatment with ergocalciferol on bone metabolism indexes in 
hemodialysis patients.
Materials and Methods. In a randomized controlled trial, 40 
hemodialysis patients were randomly allocated to the intervention 
(n = 20) and placebo (n = 20) groups. During the study, 4 patients in 
the placebo and 1 in the intervention group were excluded. Patients 
received calcitriol, 0.25 mg/d, with ergocalciferol, 50 000 IU, or 
placebo weekly for 3 months. Serum levels of 25-hydroxyvitamin 
D, calcium, parathyroid hormone, and alkaline phosphatase were 
measured before and after treatment.
Results. 25-hydroxyvitamin D levels were significantly improved 
in the intervention group (12.00 ± 4.90 ng/mL versus 29.89 ± 9.48 
ng/mL, P < .001), but the placebo group had no improvement 
(14.23 ± 7.62 ng/mL versus 13.87 ± 8.04 ng/mL, P > .05). There was 
no significant changes in serum calcium, parathyroid hormone, or 
alkaline phosphatase levels in each group. Eight patients (42.1%) 
in the intervention compared to zero cases in the placebo group 
had normal 25-hydroxyvitamin D levels after treatment (P = .004). 
No cases of hypercalcemia were seen in the studied patients.
Conclusions. Treatment with ergocalciferol could significantly 
improve vitamin D deficiency with no significant effects of serum 
calcium or parathyroid hormone levels.
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INTRODUCTION
Vitamin D deficiency or insufficiency is a 
common problem in chronic kidney disease (CKD) 
with a prevalence of more than 90% in CKD and 
end-stage renal disease (ESRD) patients.1-4 Low 
levels of vitamin D is associated with high bone 
turnover, secondary hyperparathyroidism, and 
decreased bone mineral density, muscle weakness, 
anemia, resistance to treatment with recombinant 
human erythropoietin, and increased mortality in 
ESRD patients.1-5
Different mechanism have been suggested 
for vitamin D insufficiency in CKD including 
inadequate nutritional intake, decreased sunlight 
exposure, proteinuric loss and decreased hepatic 
synthesis of 25-hydroxyvitamin D, and increased 
expression of human vitamin D 24-hydroxylase 
gene, the cytochrome P-450 enzyme that specifically 
catabolizes vitamin D and its metabolites.6-8 
Adequate production of 1,25-hydroxyvitamin D 
by renal and extrarenal 1α-hydroxylase requires 
sufficient 25-hydroxyvitamin D supply. With 
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progressive kidney function impairment, there 
is a decrease in 1,25-dihydroxycholecalciferol 
production with subsequent hypocalcemia, 
secondary hyperparathyroidism, and metabolic 
bone disease.9,10
Act ive  v i tamin  D ana logs  are  accepted 
treatments to prevent or treat the secondary 
hyperparathyroidism and mineral disorders 
among patients with ESRD. However, the Kidney 
Disease Improving Global Outcome initiative 
recommendation is to use nutritional vitamin 
D along with active forms to correct vitamin D 
deficiency in ESRD patients.11 This recommendation 
is due to the fact that the 1-α-hydroxylase enzyme 
remains active in the extrarenal tissues of ESRD 
patients, which is important for local tissue 
function.12
Nutritional inactivated vitamin D (cholecalciferol 
or ergocalciferol) has been shown to successfully 
increase serum vitamin D levels, reduce parathyroid 
hormone (PTH) levels with no risk of hypercalcemia 
or hyperphosphatemia in ESRD patients.13-16 
However, the exact effects of nutritional vitamin 
D is not yet understood. In this study, we aimed to 
evaluate the effects of treatment with ergocalciferol 
on bone metabolism indexes in hemodialysis 
patients.
MATERIALS AND METHODS
In a randomized controlled trial, 40 ESRD patients 
under hemodialysis for more than 3 months during 
2017 were recruited. All ESRD patients aged between 
20 and 70 years old with vitamin D deficiency 
and a PTH level greater than 300 pg/mL, serum 
calcium level between 8.4 mg/dL and 10 mg/dL, 
and serum phosphorus level between 2 mg/dL 
and 5 mg/dL were included. All of the patients 
were on routine hemodialysis 3 to 4 times a week 
at Bu-Ali Hospital, Ardabil, Iran. Exclusion criteria 
were malignancy, death, kidney transplantation, 
or change in mode of dialysis during the study 
period. The ethics committee of Ardabil University 
of Medical Sciences approved the study and all 
patients provided informed consent.
The patients were randomly assigned to receive 
ergocalciferol, 50000 units (intervention group, 
n = 20), or placebo (n = 2 0), weekly, and calcitriol, 
0.25 mg/d, for 3 months. Placebo was prepared 
with the same size, color, and shape. All of the 
patients were instructed to use their routine 
treatments during the study and not to restrict their 
everyday diet. Patients’ adherence to medication 
were evaluated in each visit. The patients and the 
physician evaluating the outcome of the treatments 
were blinded to the group allocation. The drug 
was given to patients by the hemodialysis nurse 
every week during the dialysis session.
Serum levels of 25-hydroxyvitamin D, calcium, 
PTH, and alkaline phosphatase were measured 
before and at the end of the study. Patients’ 
demographic findings and laboratory findings were 
recorded and compared between the two groups.
All data were analyzed using the SPSS software 
(Statistical Package for the Social Sciences, version 
16.0, SPSS Inc, Chicago, IL, USA). Results were 
expressed as mean ± standard deviation or 
percentage. Continuous data were analyzed using 
the independent t test or the Mann-Whitney U test, 
as applicable. The categorical parameters were 
compared using the chi-square test or the Fisher 
exact test. The paired samples t test was used to 
evaluate the changes before and after treatment. 
P values less than .05 were considered significant.
RESULTS
During the study, 4 patients were excluded 
from the placebo group (3 died and 1 switched 
to peritoneal dialysis), and 1 patient from the 
intervention group had kidney transplantation and 
was excluded. Final analysis was performed with 
19 patients in the intervention and 16 patients in 
the placebo group. The patients were comparable 
regarding the baseline findings (Table 1). Most of 
the patients were male in both groups with diabetic 
nephropathy as the main cause of ESRD.
Table 2 demonstrates laboratory findings before 
Characteristics
Intervention 
Group
 (n = 19)
Placebo  
Group
 (n = 16)
Age, y 51.70 ± 12.39 51.82 ± 10.16
Sex
Male 13 (68.4) 13 (81.3)
Female 6 (31.6) 3 (18.8)
Dialysis duration, y 4.55 ± 1.08 4.02 ± 1.87
Cause of kidney failure
Diabetes mellitus 10 (52.6) 7 (43.8)
Glomerulopathy 3 (15.8) 4 (25)
Tubular nephritis 2 (10.5) 2 (12.5)
Unknown 4 (21.1) 3 (18.8)
Table 1. Baseline Characteristics of Study Groups
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and after intervention and their percentage of 
change between the groups. Vitamin D levels 
were comparable between the two groups before 
intervention, while there was significantly higher 
levels of 25-hydroxyvitamin D in the intervention 
group compared to the placebo group after the 
study. Although PTH levels were significantly 
higher in the intervention group before the 
study, there was no significant difference after 
intervention. Serum PTH levels were decreased 
in the intervention group, while it was increased 
in the placebo group, with no difference in the 
percentage of change between the two groups.
The only within-group significant change was 
in 25-hydroxyvitamin D levels among the patient 
in the intervention group (P < .001).
Only 8 patients, all in the intervention group 
(42.1%), significantly improved to normal vitamin 
D ranges after treatment (P = .004). No cases of 
hypercalcemia were seen in neither of the groups.
DISCUSSION
In this study, we observed that vitamin D levels 
were significantly increased following treatment 
with ergocalciferol and calcitriol compared to those 
treated with calcitriol alone with no significant effect 
on calcium, PTH, and alkaline phosphatase. Studies 
have demonstrated that vitamin D have endocrine 
as well as paracrine and autocrine functions which 
yield to different pathophysiological effects.17,18 
Most CKD and ESRD patients have low vitamin D 
levels, which should be treated properly. It is still 
unclear whether to treat vitamin D deficiency with 
active or nutritional vitamin D. Sufficient levels of 
25-hydroxyvitamin D is necessary to provide proper 
extrarenal calcitriol production for paracrine actions. 
Also, the need for active vitamin D is increased 
with a decrease in GFR and disease progression to 
ESRD. Using nutritional and activated vitamin D 
together seems to have synergistic effects on both 
the classic and nonclassic actions.8,19.
In our study, 42% of patients treated with 
a combination of ergocalciferol and calcitriol 
reached normal vitamin D levels. Similarly, Bhan 
and coleagues16 observed a significant increase 
in 25-hydroxyvitamin D levels with weekly or 
monthly ergocalciferol, 50 000 IU. In their study, 
90% of the patients achieved vitamin D sufficiency. 
Marckmann and colleagues20 found a significant 
increase in vitamin D levels in the treatment with 
cholecalciferol, 40 000 U/wk, compared to the 
control group. In a long-term treatment period of 
a mean of 39.2 weeks, Assimon and coworkers21 
observed a higher serum 25-hydroxyvitamin D 
levels in the ergocalciferol group undergoing 
maintenance hemodialysis.
Moe and colleagues22 have noted that treatment 
with a daily dosage of 4000 IU/d of cholecalciferol 
for 1 month with 2000 IU for 2 additional months 
was sufficient to increase vitamin D levels above 
37 ng/mL and to normalize serum calcitriol in 
CKD stage 3 and 4.
We observed no episodes of hypercalcemia 
during the study period in our patients. We also 
Serum Parameters Intervention Group (n = 19)
Placebo Group
 (n = 16) P
Vitamin D, ng/mL
Before 12.00 ± 4.90 14.23 ± 7.62 .28
After 29.89 ± 9.48 13.87 ± 8.04 < .001
Percentage of change 184.52 ± 131.17 3.97 ± 26.05 < .001
Calcium, mg/dL
Before 7.99 ± 0.87 8.07 ± 0.63 .75
After 8.15 ± 0.84 8.19 ± 1.08 .91
Percentage of change 2.45 ± 7.59 1.45 ± 9.40 .73
Parathyroid hormone, pg/mL
Before 593.95 ± 212.83 390.47 ± 225.33 .008
After 518.52 ± 335.55 487.50 ± 484.39 .82
Percentage of change -7.63 ± 47.66 39.48 ± 132.80 .08
Alkaline phosphatase, mg/dL
Before 298.50 ± 182.22 264.94 ± 89.11 .49
After 310.15 ± 223.14 279.75 ± 79.43 .60
Percentage of change 11.87 ± 31.17 14.86 ± 26.61 .76
Table 2. Laboratory Findings Before and After Intervention
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found no significant change in calcium and alkaline 
phosphatase in the intervention and placebo groups. 
Hewitt and colleagues15 also found no hypercalcemia 
or hyperphosphatemia following treatment with 
cholecalciferol 50 000 IU weekly for 8 weeks. Other 
studies have shown that ergocalciferol has negligible 
effects on serum calcium and phosphorus.23-25 It 
could be concluded that treatment with nutritional 
vitamin D (ergocalciferol and cholecalciferol) 
along with active vitamin D effectively increase 
25-hydroxyvitamin D levels without increasing 
the risk of hypercalcemia or hyperphosphatemia. 
One possible explanation for the lack of calcemic 
effect could be that weekly nutritional vitamin 
D supplementation had no effect on intestinal 
absorption of calcium.26
Studies have indicated that PTH levels following 
treatment with active or nutritional vitamin D 
is significantly decreased in predialysis patients 
and lower CKD stages, but not in ESRD patients 
under hemodialysis.13 Marckmann and colleagues20 
also reported that although there was significant 
decrease in PTH levels in predialysis patients, but 
no significant changes was seen in hemodialysis 
patients. Following treatment with ergocalciferol, 
we observed a decrease in PTH levels, but an 
increase in PTH levels in placebo group; however, 
these changes were not significant. Previous 
clinical trials have also reported no effects of 
nutritional vitamin D on PTH in hemodialysis 
patients.15,16,27-31 Considering all these studies, it 
seems that nutritional vitamin D has no effect on 
PTH in patients on hemodialysis.
One study has recommended that insufficient 
dosages given cannot achieve proper level to 
decrease PTH.32 Thus, the proper dosage of 
nutritional vitamin D, either ergocalciferol or 
cholecalciferol, should be properly defined in 
ESDR patients under hemodialysis. We used the 
KDOQI guidelines of an oral weekly doses of 
50 000 IU of ergocalciferol for 12 weeks for mild to 
severe deficiency to correct vitamin D deficiency. 
However, with this protocol, only 42% of patients 
reached sufficient levels. Thus, higher doses may 
be needed to reach better responses.
We evaluated the changes in 25-hydroxyvitamin 
D levels, as in our center we are unable to measure 
25-hydroxyvitamin D2 levels and so could not 
define the exact effect of ergocalciferol on this 
measurement. Other limitation of this study 
are small sample size and shorter follow-up 
duration.
CONCLUSIONS
In conclusion, treatment with ergocalciferol could 
significantly improve vitamin D deficiency with 
no significant effects of calcium and PTH levels.
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